Versatile Vectors for Transient and Stable Expression of Recombinant Antibody Molecules in Mammalian Cells
Overview
Pathology
Authors
Affiliations
We have developed new cassette expression vectors for the cloning of any intact V-region gene followed by any C-region gene. Both the heavy-and light chain vectors harbor a strong hCMV promoter, restriction site cassettes for cloning of both V- and C-region genes, transcription termination signals, fl-ori for single stranded DNA (ssDNA) synthesis, selection marker for Neomycin and SV40 ori for transient expression. The vectors accept VH and VL chain genes obtained by RT-PCR. Reamplification of the V genes is then performed with a new set of primers which are designed specifically for each individual V gene. Cloning into the vectors is aided by restriction sites located just outside the V-gene coding region, thus keeping the V-genes intact. The vectors also contain cloning sites for the exchange of genomic C-genes so that the resulting Ig genes may code for complete antibodies, antibody fragments or fusion proteins. A simple subcloning step permits the expression of both heavy and light chain genes from one single vector, thus avoiding co-transfection of the two vectors. The usefulness of the vectors was confirmed by construction of mouse-human chimeric antibodies. The V-genes were derived from a hybridoma cell line, TP-3, and was combined with human C kappa, C gamma 3 and C gamma 1 genes as well as with CH1 gamma 3. High yields of recombinant antibody products in NSO cells were obtained. Transient expression was also demonstrated.
Foss S, Sakya S, Aguinagalde L, Lustig M, Shaughnessy J, Cruz A Nat Commun. 2024; 15(1):2007.
PMID: 38453922 PMC: 10920689. DOI: 10.1038/s41467-024-46321-9.
Hinke D, Anderson A, Katta K, Laursen M, Tesfaye D, Werninghaus I Nat Commun. 2024; 15(1):850.
PMID: 38346952 PMC: 10861589. DOI: 10.1038/s41467-024-44889-w.
Westhrin M, Blazevski J, Textor A, Abdollahi P, Gopalakrishnan R, Ngo L J Immunother Cancer. 2023; 11(8).
PMID: 37607769 PMC: 10445383. DOI: 10.1136/jitc-2023-006944.
Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.
Mukadam A, Miller L, Smith A, Vaysburd M, Sakya S, Sanford S Science. 2023; 379(6639):1336-1341.
PMID: 36996217 PMC: 7614512. DOI: 10.1126/science.abn1366.
Werninghaus I, Hinke D, Fossum E, Bogen B, Braathen R Mol Ther. 2023; 31(7):2188-2205.
PMID: 36926694 PMC: 10362400. DOI: 10.1016/j.ymthe.2023.03.012.